BRIEF—Daiichi Sankyo transfers Chinese Cravit MAA to YaoPharma

Japanese drugmaker Daiichi Sankyo has transferred its marketing authorization of the synthetic broad spectrum antibacterial agent Cravit Tablets/Injection (levofloxacin) in China to YaoPharma.

Daiichi Sankyo’s strategic focus is on patented drugs and a shift towards oncology and a strengthened cardiovascular, pain and other therapeutic business in China, where Cravit’s patent has expired and where the government promotes the use of generic drugs.

The transfer procedure is projected to be completed by the end of August 2022, following approval of the Chinese regulatory authority.